deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04680715

Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer (RPOS+2)

Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study

Sponsor: Centre Antoine Lacassagne

Updated 9 times since 2021 Last updated: Jan 28, 2026 Started: Jul 16, 2021 Primary completion: Jun 30, 2027 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Localized Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Centre Antoine Lacassagne and has accumulated 9 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshotRecruiting~Sep 2022 – ~Dec 2023 · 15 months · monthly snapshotRecruiting~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Feb 2026 · 12 months · monthly snapshotRecruiting~Feb 2026 – present · 6 months · monthly snapshotRecruiting

Change History

9 versions recorded
  1. Feb 2026 — Present [monthly]

    Recruiting PHASE2

  2. Feb 2025 — Feb 2026 [monthly]

    Recruiting PHASE2

    Phase: NAPHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Recruiting NA

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting NA

  5. Dec 2023 — Jul 2024 [monthly]

    Recruiting NA

Show 4 earlier versions
  1. Sep 2022 — Dec 2023 [monthly]

    Recruiting NA

  2. Sep 2021 — Sep 2022 [monthly]

    Recruiting NA

  3. Jun 2021 — Sep 2021 [monthly]

    Recruiting NA

    Status: Not Yet RecruitingRecruiting

  4. Jan 2021 — Jun 2021 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centre Antoine Lacassagne
Data source: Centre Antoine Lacassagne

For direct contact, visit the study record on ClinicalTrials.gov .